Alzheimer's Disease Therapeutics Market Report Research 2022: Increasing Gap of Unmet Need of Effective Therapeutics

News provided by

Jan 20, 2023, 18:20 ET

DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Alzheimer's Disease Therapeutics (2022 Edition) - Market Insight, Epidemiology and Pipeline Assessment (By Molecule Type, By Route of Administration, By Pipeline Phase)" report has been added to ResearchAndMarkets.com's offering.

Alzheimer's disease Therapeutics Pipeline Analysis has 101 active drugs undergoing several stages of clinical trials.

The Alzheimer's disease Therapeutics Pipeline is driven by an increasing gap of unmet need of effective therapeutics that can cure Alzheimer's disease. Additionally, life expectancy has increased due to various healthcare reforms in major economies such as the U.S., Japan, and China. This has resulted in a large geriatric population which is the age group most affected by the disease.

Alzheimer's prevalence is rising rapidly and despite decades of research, the disease remains incurable. The majority of therapeutics target symptom reduction and slowing the progression of the disease. The Food and Drug Administration (FDA) approved aducanumab (Aduhelm) for the treatment of certain cases of Alzheimer's disease in June 2021 and this is the first drug approved for Alzheimer's disease in decades.

Eisai, Biogen, Hoffmann-La Roche, AZTherapies, Cerecin, Neurotrope, AC Immune, Cassava Sciences, AB Science, Anavex Life Sciences, Athira Pharma, Denali Therapeutics Inc., and other notable companies are developing therapeutic candidates to improve the Alzheimer's Diagnosis and treatment scenario.

Scope of the Report

The report analyses the Alzheimer's Disease Therapeutics in Pipeline by Molecule Type (Small Molecules, Monoclonal Antibody, Vaccine, DNA/RNA Based, Natural products, Gene Therapy, Cell Therapy, Others).
The report analyses the Alzheimer's disease Therapeutics by Route of Administration (Oral, Intravenous, Intramuscular, Subcutaneous, Intrathecal, Intranasal, Other).
The report analyses the Alzheimer's disease Therapeutics by Pipeline Phase (Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Phase IV, Preclinical).
The report analyses the Pain Management Drugs Market by Availability (Over the Counter (OTC), Prescription).
The Alzheimer's Disease Therapeutics- Pipeline Analysis has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The Global Pain Management Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).
The key insights of the report have been presented through the leading company shares.
Also, the major, trends, drivers and challenges as well as Unmet Needs of the industry has been analysed in the report.
The companies analysed in the report include Eli-Lily & Co , Elsal Co., Ltd., BioVie, Johnson and Johnson, Otsuka Pharmaceutical Co., Ltd. H. Lundbeck A/S, Novartis, Cognition Therapeutics, Merck Sharp & Dohme LLC, Biogen.

Key Target Audience

Alzheimer's Disease Therapeutics Companies
End Users (Hospitals and clinics)
Research and Development (R&D) Organizations
Government Bodies & Regulating Authorities
Investment Banks and Equity Firms

Key Topics Covered:

1. Introduction
1.1 Alzheimer's Disease Therapeutics Overview
1.2 Scope of Research

2. Executive Summary
2.1 Market Dashboard
2.2 Regional Insights
2.3 Market Ecosystem Factors

3. Research Methodology
3.1 Data Collection Process
3.2 Market Size Calculation-Top-to-Bottom

4. Macro Economic Indicator Outlook
4.1 Global, Region wise GDP Growth
4.2 Global Medical Spending
4.3 Current Healthcare Expenditure
4.4 Pharmaceutical Spending/capita

5. Competitive Positioning
5.1 Companies' Product Positioning
5.2 Competitive positioning
5.2.1 Eli-Lily & Co
5.2.2 Elsal Co., Ltd.
5.2.3 BioVie
5.2.4 Johnson & Johnson
5.2.5 Otsuka Pharmaceutical Co., Ltd.
5.2.6 H. Lundbeck A/S
5.2.7 Novartis
5.2.8 Cognition Therapeutics
5.2.9 Merck Sharp & Dohme LLC
5.2.10 Biogen

6. Alzheimer's disease background
6.1 AD Fact Sheet
6.2 Epidemiology
6.3 Causes and Risk Factors
6.4 Diagnosis and Assessment
6.5 Unmet Needs

7. Therapeutics in Pipeline
7.1 Pipeline Scenario
7.2 Alzheimer's Therapeutics Comparative Review

8. Pipeline Analysis

9. Phase I therapeutics Overview
9.1 LY3372993
9.1.1 Drug Description
9.1.2 Outcomes
9.2 Lu AF87908
9.3 anle138b
9.4 ASN51
9.5 CMS121
9.6 IBC-Ab002
9.7 LX1001
9.8 MK-2214
9.9 MK-8189
9.10 ACU193
9.11 NIO752
9.12 ALN-APP
9.13 TB006
9.14 SNK01
9.15 Pepinemab
9.16 GB-5001
9.17 AC-1202
9.18 SHR-1707
9.19 BEY2153
9.20 JNJ-40346527
9.21 APNmAb005
9.22 NPT 2042
9.23 ALZ-101

10. Phase I/II therapeutics Overview
10.1 Posiphen
10.1.1 Drug Description
10.1.2 Outcomes
10.1.3 Collaborators
10.2 PrimeProT/ PrimeMSKT
10.3 TB006
10.4 RO7126209
10.5 DNL593
10.6 BIIB080
10.7 E2814
10.8 Tdap
10.9 ACI-35.030/ JACI-35.054
10.10 ACI-24.060
10.11 IVL3003

11. Phase II therapeutics Overview
11.1 Lecanemab
11.1.1 Drug Description
11.1.2 Outcomes
11.1.3 Collaborators
11.2 Lomecel-B
11.3 AL002
11.4 AL001
11.5 CT1812 (Elaya)
11.6 APH-1105
11.7 ATH-1017
11.8 T-817MA
11.9 Montelukast buccal film
11.10 ABBV-916
11.11 Bepranemab
11.12 TB006
11.13 LY3372689
11.14 MW150
11.15 EX039
11.16 JNJ-42847922
11.17 REM0046127
11.18 Bryostatin 1
11.19 NanoLithium NP03
11.20 AstroStem
11.21 Gantenerumab
11.22 Semorinemab
11.23 Obicetrapib
11.24 ALZ-801
11.25 CY6463
11.26 Crenezumab
11.27 T3D-959
11.28 PMZ-1620
11.29 GV1001
11.30 ACZ885
11.31 PQ912
11.32 APH-1105
11.33 SLS-005
11.34 Flos gossypii flavonoids
11.35 Human Mesenchymal Stem cells (MSCs)
11.36 JNJ-63733657
11.37 IGC-AD1
11.38 TW001
11.39 ABvac40

12. Phase II/III therapeutics Overview
12.1 Tricaprilin
12.1.1 Drug Description
12.1.2 Outcomes
12.2 ANAVEX2-73
12.3 Piromelatine
12.4 AGB101

13. Phase III therapeutics Overview
13.1 Simufilam
13.1.1 Drug Description
13.1.2 Outcomes
13.1.3 Collaborators
13.2 ATH-1017
13.3 Lecanemab
13.4 Nilotinib BE
13.5 Brexpiprazole
13.6 Masitinib
13.7 Remternetug
13.8 Donanemab
13.9 NE3107
13.10 Gantenerumab
13.11 GV-971
13.12 Aducanumab
13.13 TRx0237
13.14 Semagludtide
13.15 BPDO-1603
13.16 AR1001
13.17 KarXT
13.18 AXS-05

14. Phase IV therapeutics Overview
14.1 Choline Alfoscerate
14.1.1 Drug Description
14.1.2 Outcomes
14.2 Ebicomb
14.3 Rivastigmine
14.4 GV-971

15. Preclinical Phase therapeutics Overview
15.1 PMN310
15.1.1 Drug Description
15.1.2 Outcomes
15.1.3 Collaborators
15.2 PRX123

16. Pipeline analysis, By molecule type
16.1 Alzheimer's Therapeutics Comparative Review, by Molecule type

17. Pipeline analysis, By Route of Administration
17.1 Alzheimer's Therapeutics Comparative Review, By Route of Administration

For more information about this report visit https://www.researchandmarkets.com/r/rjpacl

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets